These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1503899)

  • 1. The effects of ICRF-154 in combination with other anticancer agents in vitro.
    Kano Y; Narita T; Suzuki K; Akutsu M; Suda K; Sakamoto S; Miura Y
    Br J Cancer; 1992 Aug; 66(2):281-6. PubMed ID: 1503899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of amsacrine in combination with other anticancer agents in human acute lymphoblastic leukemia cells in culture.
    Kano Y; Sakamoto S; Kasahara T; Akutsu M; Inoue Y; Miura Y
    Leuk Res; 1991; 15(11):1059-66. PubMed ID: 1961009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of SN-38 in combination with other anticancer agents against Dauji cells].
    Akutsu M; Suzuki K; Tsunoda S; Kano Y; Miura Y
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1607-11. PubMed ID: 8060135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line.
    Kano Y; Suzuki K; Akutsu M; Suda K
    Leukemia; 1992 May; 6(5):440-5. PubMed ID: 1593909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CPT-11 in combination with other anti-cancer agents in culture.
    Kano Y; Suzuki K; Akutsu M; Suda K; Inoue Y; Yoshida M; Sakamoto S; Miura Y
    Int J Cancer; 1992 Feb; 50(4):604-10. PubMed ID: 1537625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines.
    Kano Y; Akutsu M; Suzuki K; Yoshida M
    Leuk Res; 1993 Feb; 17(2):113-9. PubMed ID: 8429687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines.
    Yazawa Y; Takagi T; Asakura S; Suzuki K; Kano Y
    J Orthop Sci; 1999; 4(3):231-7. PubMed ID: 10370165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines.
    Takagi T; Yazawa Y; Suzuki K; Yamauchi Y; Kano Y
    Invest New Drugs; 1996; 14(4):357-63. PubMed ID: 9157070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines.
    Lu DY; Huang M; Xu CH; Yang WY; Hu CX; Lin LP; Tong LJ; Li MH; Lu W; Zhang XW; Ding J
    BMC Pharmacol; 2005 Jun; 5():11. PubMed ID: 15963241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.
    Pei XH; Nakanishi Y; Takayama K; Bai F; Kawasaki M; Tsuruta N; Mizuno K; Hara N
    Anticancer Drugs; 1997 Mar; 8(3):231-7. PubMed ID: 9095327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells.
    Scambia G; Della Bitta R; Benedetti Panici P; De Vincenzo R; Contu G; Ercoli A; Bonanno G; Pierelli L; Mancuso S
    Gynecol Oncol; 1995 Apr; 57(1):16-22. PubMed ID: 7705696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo.
    Wheeler RH; Clauw DJ; Natale RB; Ruddon RW
    Invest New Drugs; 1983; 1(4):283-95. PubMed ID: 6432722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Mano H; Furukawa Y
    Invest New Drugs; 2007 Feb; 25(1):31-40. PubMed ID: 16865529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines].
    Akutsu M; Suzuki K; Tsunoda S; Kano Y
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):297-302. PubMed ID: 8712822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
    Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
    Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicinal chemistry of probimane and MST-16: comparison of anticancer effects between bisdioxopiperazines.
    Lu DY; Huang M; Xu CH; Zhu H; Xu B; Ding J
    Med Chem; 2006 Jul; 2(4):369-75. PubMed ID: 16848748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.